http://www.reportlinker.com/p097881/World-Pharmaceuticals-Market-Brief.html

The global outlook series on Pharmaceuticals provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report provides a bird's eye view of the pharmaceutical industry, and highlights global trends impacting the marketplace, such as, patent expiry of blockbuster global drugs, rising demand for old age related medications and cardiovascular drugs, and the rise of biogenerics, among others. A briefly summarized outlook presents unequivocal views on the industry's future. Punctuated with 18 statistically rich tables, the global market discussion offers special preludes to major market segments, such as, Prescription Drugs, Blockbuster Drugs, Anti-Depressants, COPD, Cholesterol Drugs, CNS Drugs, Cardiovascular Drugs, Cancer Drugs, Attention Deficit Hyperactive Disorder, Artherosclerosis, Asthma, Anti-Infective Prescription Agents, Receptor Blockers, Psychotic Disorders, Osteoporosis, Multiple Sclerosis, Irritable Bowel Syndrome, Insomnia, Immunosupression Hypertension, Epilepsy, Rhinitis, Urinary Disorders, HIV/AIDS, and Diabetes among others. Also included is a recapitulation of recent mergers, acquisitions, and other noteworthy strategic corporate developments. Annotated with quantitative analysis and research findings, the discussion on the US market contains 46 market data tables designed to give the reader a macro level understanding of the market. Other regional markets covered include Canada, Japan, Western Europe, Switzerland, UK, China, India, Korea, Malaysia, and Brazil. The purpose of the abstracted regional market discussion is to provide the reader an introduction to these markets. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 3,083 companies worldwide.

PHARMACEUTICALS GOS-041 A GLOBAL OUTLOOK, SEPTEMBER 2008

CONTENTS

1. Overview 1

Table 1: Global Pharmaceutical Market (2006): Sales in US$ Billion by Region - US, Europe, Japan, Asia-Pacific, Latin America, Middle East/Africa and Canada 1 US Leads the Pharmaceuticals Sector 1 Global Trends in Pharmaceutical Industry 1 Aging World Population Drives Up Demand for Pharmaceuticals 1 Market Booming for Old Age Related Medications 2 BRIC Countries to Drive Up the Pharmaceuticals Sector 2 China and India Emerge as Major Contract Manufacturing Hubs 2 Rising Consumer Health Consciousness Drives Up the OTC Drugs Sector 2 Market Growing for OTC Scar Management Solutions 3 Market Growing for Artificial Tears 3 Faster Drug Approval Process, the Need of the Hour 3 Cardiovascular Drugs Still Rules the Roost 3 Global Analgesics Market to Soar 3 Market Growing for Antidepressants 4 New R&D Initiatives To Spark Up Growth 4 Acquisitions and Mergers Propels the Pharmaceuticals Sector 5 Generics Expand Share 5

Table 2: Increasing Share of Generics in the Global Pharmaceutical Market: 1995-2006 (In %) 6

Table 3: Global Generic Drugs Market by Geographic Region: Annual Sales Estimates in US$ Million for 2003 through 2008 for USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World 6

Table 4: Global Generic Drugs Market (2005 & 2006): Percentage Breakdown of Value Sales by Therapeutic Category - Cardiovascular, Anti-Infective, Analgesic, Central Nervous System (CNS), Gastrointestinal, Cancer, Respiratory & Anti-Allergic, and Others 7 Global Patent Expiries of Select Major Drugs: 2007-2012 7 Major Generic Drugs 8

Table 5: Leading Generic Drugs Worldwide by Retail Sales (2005): Hydrocodone/APAP, Gabapentin, Amoxicillin/pot. clav., Paroxetine, Oxycodone, Lisinopril, Metformin, Omeprazole, Fentanyl transdermal, Amoxicillin, Fluoxetine, Oxycodone w/ APAP, Albuterol aerosol, Lovastatin, Levothyroxine, Lorazepam, Atenolol, Alprazolam, Cephalexin, and Warfarin 8

Table 6: Leading Generic Drugs Worldwide by Total Units Dispensed (2005): Annual Estimates in Millions for Hydrocodone/APAP, Amoxicillin, Peg 3350/electrolyte, Metformin, Alprazolam, Lisinopril, Atenolol, Hydrochlorothiazide, Furosemide Oral, Chlorhexidine Gluconate, Gabapentin, Ibuprofen, Levothyroxine, Metoprololtartrate, Albuterol nebulizer solution, Propoxyphene-N/APAP, Potassium chloride, Cephalexin, Amoxicillin/pot. Clav., and Tramadol 9 Leading Generic Drug Companies 10

Table 7: Leading Companies in the Global Generic Drugs Market (2005): Percentage Breakdown by Value Sales for Sandoz, Teva Pharmaceutical Industries, Merck Generics, Actavis, Ratiopharm, Mylan Laboratories, IVAX, Barr Pharmaceuticals, Ranbaxy Laboratories, and Others 10

Table 8: Leading Companies in the Global Generics Pharmaceutical Market by Number of Prescriptions Dispensed (2005): Annual Estimates in Millions for Teva/Ivax, Mylan, Sandoz, Watson, Mallinckrodt, Alpharma, Qualitest, Par, Barr, Laboratories, and URL/Mutual 10 Generic Competition Provides the Necessary Momentum 11 Authorized Generics - A Major Concern for Generic Makers 11 Regulatory Reform Drive the European Market 11 New Areas of Expertise 11 Biogeneric Revolution 11 Bio-generics to Exhibit Slow Start 11 Biogeneric Market Trends Worldwide: 2005-2010 12 Select Global Biotech Drugs Off-Patent: 2001-2006 12 Potentially Key Competitors in the Biogenerics Space: 2005-2010 12 Product Lifecycle Management - The Deciding Factor 13

Table 9: TOP 10 Pharmaceutical Products Worldwide in 2004 13 Packaging Trends 14 Blister Packaging to Record High Growth 14

Table 10: Global Pharmaceutical Packaging Demand by Country: Percentage Market Share for 2005, 2008, and 2010 for Europe, North America, Latin America, and Others 14 Outlook 15 Pharmacogenomics to Substitute Pharma's Business Model 15 Biopharmaceuticals - The Next Generation 15

Table 11: Global Demand for Biopharmaceuticals: Annual Market Estimates for 2004 through 2010 in Millions of Liters 16 Nano-Enabled Drug Discovery Geared to Lead 16 Proteomics - The Current Spotlight 16 Neurodegeneration Treatments Identified in Research 17

Table 12: Leading Companies in the Global Pharmaceutical Market by Healthcare Research and Development (R&D) Spending (2005): Annual Estimates in US$ Million for Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc, Sanofi-Aventis Group, Novartis, Roche, Merck & Co., AstraZeneca Plc, Eli Lilly and Co., Wyeth, Bristol-Myers Squibb Co., Amgen Inc., Schering-Plough Corp., Abbott Laboratories, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Co., Daiichi Sankyo Co., Genentech Inc., Schering AG, and Astellas Pharma Inc. 17

2. Major Class of Drugs 18 Antidepressants 18 Antiepileptics 18 Antipsychotics 18 Antirheumatic Non-steroidals 18 Antulcerants 18 Calcium Antagonists 18 Erythropoietins 18 Oral Antibiotics 18 Lipid Regulators 18 Antiarthritics 18 Antihistamines 18 Antihyperlipidemics 18 Oral Antidiabetics 18

3. Geographical Landscape 19

Table 13: Global Pharmaceutical Market by Region/Country (2005): Annual Sales in US$ Billion for United States, Europe, Japan, Asia-Pacific, Latin America, Middle East/Africa, and Canada 19

Table 14: Global Pharmaceutical Market by Region/Country (2005): Percentage Breakdown of Value Sales for United States, Europe, Japan, Asia Pacific, Latin America, Middle East/Africa, and Canada 19 Leading Global Pharmaceutical Players 19

Table 15: Leading Global Pharmaceutical Companies by Revenue (2006): Annual Estimates in US$ Billion for Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis, Johnson & Johnson, AstraZeneca, Merck, Roche, Abbott, and Amgen 20

Table 16: Leading Global Pharmaceutical Companies by Net Income (2005): Annual Estimates in US$ Million for Johnson & Johnson, GlaxoSmithKline Plc, Procter & Gamble Co., Pfizer Inc., Novartis, Roche, AstraZeneca Plc., Merck & Co., Amgen Inc., Wyeth, Abbott Laboratories, Bristol-Myers Squibb Co., Sanofi-Aventis Group, Takeda Pharmaceutical Co., and Bayer 20

Table 17: Leading Global Pharmaceutical Companies by Market Capitalization (2006): Annual Estimates in US$ Million for Pfizer Inc., Procter & Gamble Co., Johnson & Johnson, GlaxoSmithKline Plc., Novartis, Sanofi-Aventis Group, AstraZeneca Plc, Merck & Co., Genentech Inc., Amgen Inc., Abbott Laboratories, Wyeth, Eli Lilly and Co., Bristol-Myers Squibb Co., and Bayer 21

Table 18: Leading Global Pharmaceutical Companies by Shareholders' Equity (2005): Annual Estimates in US$ Million for Pfizer Inc., Procter & Gamble Co., Sanofi- Aventis Group, Johnson & Johnson, Roche, Novartis, Amgen Inc., Takeda Pharmaceutical Co, Merck & Co., Abbott Laboratories, Bayer, AstraZeneca Plc., GlaxoSmithKline Plc., Wyeth, and Bristol-Myers Squibb Co. 21

Table 19: Leading Global Pharmaceutical Companies by Aggregate Assets (2005): Annual Estimates in US$ Million for Procter & Gamble Co., Pfizer Inc., Sanofi-Aventis Group, Johnson & Johnson, Novartis, Roche, GlaxoSmithKline Plc., Bayer, Merck & Co., Wyeth, Amgen Inc., Abbott Laboratories, Bristol-Myers Squibb Co., Takeda Pharmaceutical Co., and AstraZeneca Plc 22

Table 20: Leading Global Pharmaceutical Companies by Number of US-dispensed Prescriptions (2005): Annual Estimates in Millions for Pfizer, Novartis, Teva, Mylan Laboratories, Watson, GlaxoSmithKline, Merck & Company, Ivax Corporation, AstraZeneca, Mallinckrodt, Johnson & Johnson, Sanofi-Aventis, Barr Laboratories, Abbott Laboratories, and Alpharma USPD 22

Table 21: Leading Global Pharmaceutical Companies by Direct-to-consumer Advertisement Spending (2005): Annual Estimates in US$'000 for GlaxoSmithKline, Pfizer, AstraZeneca, Sanofi-Aventis, Merck & Co., Johnson & Johnson, Novartis, Sepracor, Merck/Schering-Plough Pharmaceuticals, Amgen, Schering-Plough, Allergan, Lilly Icos, Abbott Laboratories, Wyeth, Eli Lilly, Roche, Procter & Gamble, Tap Pharmaceutical Products, and Astellas Pharma 23

4. Mergers and Acquisitions 24

5. Strategic Corporate Developments 76

6. Product Launches 105

7. Review of Select Segments 109 Prescription Drugs 109 Market Overview 109

Table 22: Global Leading Prescription Drug Brand Sales by Category: Annual Market Estimates for 2003 through 2008 in Billions of US$ for Cardiovascular, Hypertension Drugs, Anti-Infective, Psychotherapeutic Agents, Gastrointestinal Therapies, Respiratory Products, and Cholesterol Reduction. 109

Table 23: Global Leading Prescription Drugs Sales by Therapeutic Category (Blood Modifiers): Annual Market Estimation for 2003 through 2008 in Millions of US$ for Anemia, Deep Vein Thrombosis, Hemophilia, Occlusive Arterial Disease, Pulmonary Embolism, Leukopenia, Iron Intoxication, White Blood Cell Enhancement and Peripheral Disease. 110 Blockbuster Drugs 110 Market Overview 110

Table 24: Global Drugs Gaining Blockbuster Status by Sales: Annual Market Estimates for 2003 through 2008 in Billions of US$ for Advair/Seretide, Nexium, Plavix, Singulair, Mabthera/Rituxan, Lovenox/ Clexane, Ambien/Stilnox, Wellbutrin, and Others 111

Table 25: Global Top-Selling Drugs Value Sales: Annual Market Estimates for 2003 through 2008 in Billions of US$ for Chiral, Racemic, and Achiral Drugs 112 Antidepressants 112 Market Overview 112 Leading Antidepressants Worldwide and Year of Patent Expiry 112 Chronic Obstructive Pulmonary Disease 113 Market Overview 113

Table 26: Global Chronic Obstructive Pulmonary Disease Drug Sales by Leading Category: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Beta2-agonists, Anticholinergics, Corticosteroids, Methyl Xanthines and Leukotinene Antagonists 113 Cholesterol Drugs 113 Market Overview 113 Leading Cholesterol Drugs Worldwide and Year of Patent Expiry 114 CNS Drugs 114 Market Overview 114

Table 27: Global Leading Central Nervous System Prescription Drugs Sales by Symptoms: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Depression, Psychotic disorders, Epilepsy, Migraine, Insomnia, Anesthesia, Anxiety, Alzheimer disease, Attention deficit hyperactivity disorder, and Dystonia 114 Cardiovascular Drugs 115 Market Overview 115 Leading Cardiovascular Prescription Drugs 115 Cancer Drugs 115 Market Overview 115 Attention Deficit Hyperactive Disorder 115 Market Overview 115 Artherosclerosis 115 Market Overview 115 Asthma 115 Market Overview 115 Leading Brands 116 Asthma Drug Sales by Respiratory Category 116

Table 28: Global Asthma Drug Value Sales by Respiratory Category: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Inhaled Corticosteroids, Short Acting Beta Agonists, Long Acting Beta Agonists, Combinations, Anti-Leukotrienes and Other Asthma Therapeutics 116 Antinfective Prescription Agents 116 Market Overview 116

Table 29: Global Leading AntInfective Prescription Agents Sales for Various Symptoms: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Bacterial Infections, Viral Infections and Fungal Infections 117 Receptor Blockers 117 Market Overview 117

Table 30: Receptor Blockers Value Sales in the Global Market: Annual Market Estimates for 2003 through 2008 in Billions of US$ 117 Psychotic Disorders 118 Market Overview 118 Worldwide Leading Prescription Drugs for Psychotic Disorders and Year of Patent Expiry 118 Osteoporosis 118 Market Overview 118 Multiple Sclerosis 118 Market Overview 118

Table 31: Global Sales of Leading Prescription Drugs for Multiple Sclerosis in Millions of US$:) 2005 119

Table 32: Global Leading Prescription Drug Sales for Multiple Sclerosis: Annual Market Estimates for 2003 through 2008 in Millions of US$ 119 Irritable Bowel Syndrome 119 Market Overview 119

Table 33: Global Leading Drug Value Sales by Category for Treating Irritable Bowel Syndrome: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Laxatives, Antidiarrheals, and Antidepressants 120

Table 34: Global Leading Drug Value Sales by Category for Treating Irritable Bowel Syndrome: Percentage Market Share for 2004 and 2008 for Laxatives, Antidiarrheals, and Antideoressants 120 Insomnia 121 Market Overview 121 Immunosuppression 121 Market Overview 121

Table 35: Global Leading Prescription Drugs for Immunosuppression by Sales: Annual Market Estimates for 2003 through 2005 in Millions of US$ for Neoral/ Sandimmun, Cellcept, Prograf and Medrol 121 Hypertension 121 Market Overview 121

Table 36: Global Value Sales of Leading Prescription Drugs for Hypertension: 2004 and 2005 in Millions of US$ for Norvasc (Pfizer), Diovan/Co-Diovan (Novartis), Cozaar and Hyzaar (Merck & Co.), Prinivil and Prinzide (Merck & Co.), Lotensin/Cibacen and Lotrel (Novartis), Toprol-XL/Seloken (AstraZeneca), Tritace/Delix, Blopress (Takeda Chemical Industries), Zestril (AstraZeneca), Vasotec and Vaseretic (Merck & Co.), and Accupril and Accuretic (Pfizer) 122 Epilepsy 122 Market Overview 122 Leading Prescription Drugs for Epilepsy and Year of Patent Expiry 123 Rhinitis 123 Market Overview 123 Urinary Disorders 123 Market Overview 123

Table 37: Global Leading Prescription Drugs Sales for Urinary Disorders by Symptoms: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Benign Prostatic Hypertrophy and Overactive Bladder 123 HIV/AIDS 124 Market Overview 124 FDA Sanctions Fast Track Status to First-in-Class HIV Drug 124 Diabetes 124

Table 38: Global Sales of Medications for Diabetes by Segment: Percentage Market Share for 2005, 2008, and 2010 for Oral Ant Diabetic Drugs, and Insulin Products 124

Table 39: Global Sales of Medications for Diabetes by Segment: Annual Market Estimates for 2004 through 2010 in Billions of US$ for Oral Anti Diabetic Drugs, and Insulin Products 124

8. United States 125

Table 40: US Drug Market (2006): Chain Drug Stores Sales in US$ Billion by Product Category-Total Prescription (Prescription drugs--brand, Prescription drugs--brand, specialty, Prescription drugs--generic), Nonprescription drugs, Health and personal care, General merchandise, DME and HHC and Other 125

Table 41: US Pharmaceutical Market (2006): Percentage Breakdown of Value Sales by Therapic Category- Lipid Lowerers--Statins+ZET, Proton Pump Inhibitors, Anti-Depressants, Antipsychotics, 0TH, Erythropoietins, Seizure Disorders, Antineo Monoclonal Antib, Angiotensin II Antag, Insulin Sensitizer, Calcium Blockers, Antiarth, BIOL RESPMOD, Bisphosphonates, Anti-Platelets, Oral, Immune System Adjuncts, Steroid, Inhaled BronchC, ACE Inhibitors, Non-Barb, 0TH, GI Anti- Inflammatory, Aanaleptics, Immunologic Interferons and Others 126 Lower Margins in the US leads to Consolidation and Diversification in the Global Market 126 Beset with Setbacks 126 Regulations Shaping the US Pharmaceutical Industry 127 Medicare Drug Improvement and Modernization Act (MMA) 127 The American Jobs Creation Act of 2004 127 Autonomous Panel for Screening Drug Safety 127 GPhA Drives FDA to Back Generic Drugs 127 Rapid Surge in ANDAs 127 Competitive Scenario 127

Table 42: US Pharmaceutical Market (2006): Sales In US$ Million for Major Distributors- McKesson Pharmaceutical Solutions, Cardinal Health, AmerisourceBergenDrug, Kinray and HD Smith Wholesale Drug 128

Table 43: Leading Pharmaceutical Companies in the US by Branded Drug Sales (2006): Annual Estimates in US$ Million for GlaxoSmithKline, Abbott, Forest, Monarch, Dey Laboratories, Bausch & Lomb, Ivax Laboratories, Roxane, Taro USA, Par, Mylan, Repacker, Bertek, Alpharma US, Mallinkrodt, Xanodyne, Pharmaderm, Morton Grove, Dava, and Lupin 129

Table 44: Leading Pharmaceutical Companies in the US by Total Drug Sales (2006): Annual Estimates in US$ Million for GlaxoSmithKline, Teva USA, Abbott, Mylan, Sandoz, Watson Laboratories, Forest, Par, Barr, Ivax, Greenstone, Monarch, Mallinkrodt, Ranbaxy, Apotex, Eon Laboratories, Qualitest, Endo Generic, Pliva, and Danbury 130

Table 45: Leading Vendors in the US Athlete's Foot/foot Care Medication Market (2006): Sales through Drugstores in US$' 000 for Schering-Plough, Novartis Consumer Health, NDC Laboratories, Combe, Miracle of Aloe, Taro Pharmaceuticals, Chattem, Del Laboratories, Eulactol USA, and Alva/Amco 130

Table 46: Leading Vendors in the US Athlete's Foot/foot Care Medication Market (2006): Sales through Drugstores in '000 Units for Schering-Plough, Novartis Consumer Health, Combe, Chattem, Del Laboratories, Taro Pharmaceuticals, Miracle of Aloe, Eulactoi USA, Pfizer, and NDC Laboratories 131 Pharmaceuticals Market by Therapeutic Category 131

Table 47: United States Pharmaceuticals Market by Leading Therapeutic Category (2005): Annual Sales in US$ Billion for Statins, Proton Pump Inhibitors, Antipsychotics, Antidepressants, Erythropoietins (cancer), Seizure Disorders, Angiotensin II Antagonists (anti-hypertensives), Calcium blockers, Insulin Sensitizers, and Monoclonal antibodies (cancer) 131

Table 48: United States Pharmaceuticals Market (2005): Percentage Breakdown of Drug Spending by Therapeutic Category - Cardiovascular, CNS: Neurology, Mental Health & Pain, Gastro-enterology, Respiratory & Allergy, Endocrine & Diabetes, Anti-infectives, Rheumatology & Musculoskeletal, and Others 132 Leading Drugs 132

Table 49: Leading Branded Drugs in the US Pharmaceuticals Market (2005): US Sales in US$ Billion for Lipitor, Zocor, Nexium, Prevacid, Advair, Plavix, Zoloft, Epogen, Procrit, and Aranesp 132

Table 50: Leading Drug Classes by Prescriptions Volume in the US: Annual Market Estimates for 2003 through 2008 in Millions of Numbers for Codeine & Comb Non-Inj, Ssris / Snris, Cholest Rdcr Statins, Ace Inhib W / O Diuret, Beta-Blockers, O /C Estr / Progest, Calcium Blockers, Thyroid. Synthetic, Antihistamine Cap-Tab, and Proton Pump Inhibitors 133

Table 51: Leading Brands in the US First Aid Ointments/antiseptics Market (2006): Sales through Drugstores in US$'000 for Neosporin Plus, Neosporin, Mederma, Aquaphor, Polysporin, Solarcaine, Hibiclens, Betadine, BD, and Bactine 133

Table 52: Leading Brands in the US First Aid Ointments/antiseptics Market (2006): Sales through Drugstores in '000 Units for Neosporin Plus, Neosporin, BD, Aquaphor, Polysporin, Solarcaine, Mederma, Bactine, Hibiclens, and Bladex 134

Table 53: United States' Leading Cough Syrup Brands (2005): Sales through Drugstores in US$ Million for Robitussin OM, Delsym, Robitussin, Vicks NyQuil Cough, Diabetic Tussin, Zicam, Cough Mist, Vicks Formula 44, Vicks Formula 44e, Robitussin Pediatric, and Robitussin Honey Cough 134

Table 54: United States' Leading Cough Syrup Brands (2005): Sales through Drugstores in Units for Robitussin OM, Robitussin, Delsym, Vicks NyQuil Cough, Vicks Formula 44, Vicks Formula 44e, Diabetic Tussin, Robitussin Pediatric, Robitussin Honey Cough, Zicam Cough Mist 135

Table 55: Leading Brands in the US Ear Drops/treatments Market (2006): Sales through Drugstores in US$ for Similasan, Debrox, Murine, Hyland, Swim Ear, Physicians Choice, Auro Dri, Otix, Auro, and Clear Tinnitus 135

Table 56: Leading Brands in the US Ear Drops/treatments Market (2006): Sales through Drugstores in Units for Similasan, Debrox, Swim Ear, Murine, Auro Dri, Hyland, Physicians Choice, Otix, Auro, and Clear Tinnitus 135

Table 57: United States' Leading Oral Pain Relief Brands (2005): Sales through Drugstores in US$'000 for Orajel, Anbesol, Baby Oraj, Peroxyi, Zilactin, Temparin, Glyoxide, Dentemp, Kank-A, and Hyland's 136

Table 58: United States' Leading Oral Pain Relief Brands (2005): Sales through Drugstores in '000 Units for Orajel, Anbesol, Baby Orajel, Peroxyl, Temparin, Dentemp, Hyland's, Zilactin, Kank-A, and Glyoxide 136

Table 59: Leading Brands in the US Weight Control Candy/Tablet Market (2005): Sales through Drug Stores in US$ Million for Relacore, Cortislim, Zantrex 3, Trim Spa X32, Hydroxycut, Trim Spa, Xenadrine EFX, Metabolife Ultra, Estrin D, and Stacker 2 137

Table 60: Leading Brands in the US Weight Control Candy/Tablet Market (2005): Sales through Drug Stores in Units for Relacore, Trim Spa X32, Cortislim, Zantrex 3, Metabolife Ultra, Hydroxycut, Xenadrine EFX, Stacker 2, Trim Spa, and Estrin D 137

Table 61: United States' Leading Nasal Aspirator Brands (2005): Sales through Drug Stores in US$ for Luv N Care, First Years, Safety 1st, Little Noses, Ross, Gerber, Sunmark, Cara, and Acu Life 138

Table 62: United States' Leading Nasal Aspirator Brands (2005): Sales through Drug Stores in Units for Luv N Care, First Years, Safety 1st, Little Noses, Gerber, Ross, Sunmark, Cara, and Acu Life 138

Table 63: Leading Brands in the US Eye/Lens Care Solutions Market (2006): Sales through Drug Stores, Supermarkets, and Discount Stores (excluding Wal-Mart) in US$ Million for Alcon Opti-Free Express, Bausch & Lomb Renu Multiplus, Amo Complete Moisture Plus, Alcon Systane, Allergan Refresh Tears, Clear Eyes, Alcon Opti-Free Replenish, Ciba Vision Clear Care, Visine Advanced Relief, and Visine 139

Table 64: Leading Brands in the US Eye/Lens Care Solutions Market (2006): Sales through Drug Stores, Supermarkets, and Discount Stores (excluding Wal-Mart) in Million Units for Alcon Opti-Free Express, Bausch & Lomb Renu Multiplus, Clear Eyes, Visine Advanced Relief, Visine, Amo Complete Moisture Plus, Alcon Opti-Free Replenish, Alcon Systane, Ciba Vision Clear Care, and Allergan Refresh Tears 139 Consumer Healthcare 140

Table 65: Pharmaceutical Product Sales by Category through Food, Drug and Mass Merchandise Stores in the US: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Vitamins, Cold/Allergy/Sinus Tablets, Skin Care, Gastrointestinal - Tablets, Weight Control/ Nutrition Liquid/ Powder, First Aid Accessories, Miscellaneous Health Remedies, First Aid Treatment, Cold/Allergy/Sinus Liquids, Gastrointestinal - Liquid and Cough Drops 140 Packaging 140

Table 66: Pharmaceutical Industry's Packaging Demand by Type in the US: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Blister Packaging, Plastic Bottles, Secondary Containers and Other Primary Containers 140 Leading Distribution Channels 141

Table 67: United States' Pharmaceuticals Market by Retail Outlet (2005): Percentage Breakdown of Value Sales for Traditional Drug Chains, Mail Order/Internet, Independent Drug Stores, Supermarkets, and Mass Merchants 141

Table 68: Prescription Pharmaceutical Sales through Retail/Distribution Channel in the US: Percentage Market Share for 2004 and 2005 for Chains, Indep., Non-Fed Hosp., Mail Order, Food Stores, Clinics, LTC, HMO, Fed. Facilities, and Others 141

Table 69: Leading Pharmacy Chains in the United States (2005): Retail Rx Sales in US$ Million for CVS Corp., Walgreens, Wal-Mart, Rite Aid, Brooks-Eckerd, Kroger, Supervalu, Safeway, Medicine Shoppe, and Sears Holdings 142 Promotional Expenditure 142

Table 70: United States' Pharmaceutical Advertising Expenditure through Medical Journals for 2003 through 2005 (In US$ '000) 142 External Analgesics 143

Table 71: External Analgesics Sales through Distribution Channel in the US: Percentage Market Share for 2004 and 2005 for Mass Merchandise, Food and Drug Stores 143

Table 72: Leading External Analgesics Drug Brand Volume Sales in the US: Percentage Market Share for 2004 and 2005 for Bengay, Joint-Ritis, Icy Hot, Aspercreme, Flex All 454, Mineral Ice, Salonpas, Absorbine Jr., Sportscreme, and Others 143 Internal Analgesics 144

Table 73: United States' Leading Internal Analgesic Liquid Brands (2005): Sales through Drugstores in US$ Million for Children's Motrin, Tylenol, Children's Tylenol, Infant's Motrin, Children's Advil, Advil, Gel Stat, Tylenol PM, Elixsure, and Motrin 144

Table 74: United States' Leading Internal Analgesic Liquid Brands (2005): Percentage Breakdown of Volume Sales through Drugstores for Children's Motrin, Tylenol, Children's Tylenol, Infant's Motrin, Children's Advil, Advil, Gel Stat, Tylenol PM, Elixsure, and Others 144 Cancer Therapeutics 145

Table 75: Number of New Cases of Cancer Reported in the US: 2005 in Thousands for Non-melanoma Skin Cancer, Recurrent Colon Polyps, Prostate Cancer, Superficial Bladder Cancer, Barrett's Esophagus Cancer, and Others 145

Table 76: Top Cancer Incidence Types in the US: 2005 per 100,000 People for Prostate, Breast, Lung, Colon & rectum, and Testis 145 Generic Drugs 146 Market Highlights 146

Table 77: United States Market for Generic Drugs by Therapeutic Category: Annual Sales Estimates in US$ Million for 2003 through 2008 for Cardiovascular, Analgesic, Anti-Infective, Central Nervous System (CNS), Gastrointestinal, Respiratory & Anti- Allergic, Cancer and Others 146

Table 78: United States Generic Cardiovascular Drugs Market (2005): Percentage Share Breakdown by Segment - Beta Blockers and ACE Inhibitors; Calcium Channel Blockers; Angina and Arrhythmia Drugs; Diuretics; Vasodilators, Vasopressors, and Anticoagulants 147

Table 79: United States Generic Central Nervous System (CNS) Drugs (2005): Percentage Breakdown by Segment - Sedatives/Hypnotics, Tranquilizers and Antianxiety Agents, Antidepressants, Stimulants, and Antipsychotics, and Anticonvulsants, Antispasmodics and Muscle Relaxants 147

Table 80: United States Generic Gastrointestinal Drugs (2005): Percentage Breakdown by Segment - Anti-Spasmodics Drugs, Anti-Nauseants, Anti-Ulcer, Digestants, and Anti-Diarrheals 148

Table 81: United States Market for Generic Ophthalmic Drugs (2005): Percentage Breakdown by Segment - Glaucoma Drugs, Anti-Infective, and Anti- Inflammatory Drugs and Mast Cell Inhibitors 148 Leading Generic Manufacturers 148

Table 82: Leading Manufacturers in the US Generic Drugs Market (2006): Percentage Breakdown by Prescriptions for Teva, Mylan, Watson, Sandoz, Barr, Mallinckrodt, Actavis, Qualitest, Par, Greenstone and Others 148

Table 83: Leading Players in the US Generic Drugs Market (2005): Percentage Breakdown of Value Sales for Teva, Novartis (Sandoz), Mylan, Watson, Ivax, Par, Pfizer (Greenstone), Actavis, Boehringer Ingelheim, Baxter Healthcare, and Others 149 Leading Drugs by Value Sales 149

Table 84: Leading Generic Drug in the US: 2005 Percentage Market Share for Hydrocodone/ APAP, Ranitidine HCI, Albuterol aerosol, Alprazelam, Lorazepam, Atenolol, Propoxyphene- N/APAP, Tamoxifen, Cephalexin, & Others 149 Authorized Generics 150

Table 85: United States Generics Market (2003-2005): Growing Share of Authorized Generics in the Total Market 150 Diabetes 150 Oral Diabetes Drugs 150 Key Players 150

9. Canada 151 Market Overview 151 Amendments to Canadian Drug Patent Laws 151 New Regulations Provide Accurate Timeline for Introduction of Generics 151

Table 86: Canadian Market for Generic Drugs: Annual Sales Estimates in US$ Million for Years 2003 through 2008 152

Table 87: Share of Generic and Branded Drugs in the Canadian Prescription Drug Market: 2006 152

10. Japan 152 Market Overview 152

Table 88: Japanese Pharmaceuticals Market (2005): Percentage Breakdown of Value Sales by Sector - Cardiovascular, Alimentary/ metabolism, Central Nervous System, Respiratory, and Others 153

Table 89: Japanese Pharmaceuticals Market: Percentage Share of Bio-Pharmaceuticals in Total Drug Approvals for 2003, 2005, and 2008 153 Trends in Oncology Market 153

Table 90: Oncology Treatment in the Japan: Annual Market Estimates for 2003 through 2008 in Billions of US$ 153

11. Europe 154 Market Overview 154

Table 91: European Pharmaceutical Market (2006): Sales in US$ Billion by Region- France, Germany, UK, Italy and Rest of Europe 154

Table 92: Natural Ingredients Imports by Product Group in the European Union: 2005 in Millions of Euros for Medicinal and Aromatic Plants, and Others 154 Investments in R & D 154 Generic Drugs 155

Table 93: European Market for Generic Drugs by Therapeutic Category: Annual Sales Estimates in US$ Million for 2003 through 2008 for Cardiovascular, Analgesic, Anti-Infective, Central Nervous System (CNS), Gastrointestinal, Respiratory & Anti-Allergic, Cancer and Others 155

11 a. Western Europe 155 Market Overview 155 Export Scenario 155 Research and Development Expenditure 156

Table 94: Pharmaceutical Research and Development Expenditure by Country in Western Europe: Percentage Market Share for 2003, 2004 and 2005 for France, Germany, UK, Switzerland, Belgium, and others 156 Generic Drugs 156

Table 95: Western European Market for Generic Drugs by Country: Annual Sales Estimates in US$ Million for 2003 through 2008 for France, Germany, UK, Spain, and Italy 156

11b. Switzerland 157 Market Overview 157

11c. United Kingdom 157 Market Overview 157

Table 96: United Kingdom Pharmaceuticals Market (2003-2005): Exports and Imports in GBP Million 157 Over-The-Counter Medications 158

Table 97: Over-the Counter Volume Sales of Drugs by Category in the UK: Annual Market Estimates for 2003 through 2008 in Millions of Units for Gastro/ Intestinal, Cold/Cough, Eye Care/Hayfever, Oral/ Topical Analgesics, FAD/Topical Antiseptics and Other Defined Healthcare 158

Table 98: Over-the Counter Volume Sales of Drugs by Category in the UK: Percentage Market Share for 2004 and 2008 (E) for Gastro/ Intestinal, Cold/Cough, Eye Care/Hayfever, Oral/Topical Analgesics, FAD/Topical Antiseptics and Other Defined Healthcare 159

Table 99: Over-The-Counter Medication Value Sales in the UK: Annual Market Estimates for 2003 through 2008 in Millions of Pounds Sterling for Pain Relief, Skin Treatments, Cough/Cold/Sore Throat, Gastro-Intestinal, Vitamins & Minerals, Medicated Mouthwash/ Sprays, Hayfever Remedies, Eye Care Treatment and Sleeping Aids 159

Table 100: Over-The-Counter Medication Value Sales in the UK: Percentage Market Share for 2004 and 2008 for Pain Relief, Skin Treatments, Cough/Cold/Sore Throat, Gastro-Intestinal, Vitamins & Minerals, Medicated Mouthwash/Sprays, Hayfever Remedies, Eye Care Treatment and Sleeping Aids 160 Analgesics 160

Table 101: Analgesics Value Sales through Drug Stores in the UK: Annual Market Estimates for 2003 through 2008 in Millions of Pounds Sterling for Adult Oral Analgesics, Pediatric Analgesics, and Topical Analgesics 161 Oral Analgesics 161 Statin Drugs 161

Table 102: Leading Statin Drugs Average New Prescriptions in the UK: 2004 2005 Percentage Market Share for Lipitor, Zocor, Pravachol, Baycol, Lescol, and Mevacor 162

12. Asia/Asia-Pacific 162 Market Overview 162

Table 103: Asian Pharmaceuticals Market (2005): Percentage Breakdown of Value Sales by Geographic Region/Country - Japan, China, Australia, South Korea, and Rest of Asia-Pacific 162 Generic Market - A Perspective 163

12a. China 163

Table 104: Chinese Pharmaceuticals Market: Annual Sales in US$ Billion for 2003 through 2005 164

Table 105: Chinese Market for Generic Drugs: Annual Sales Estimates in US$ Million for Years 2003 through 2008 164

Table 106: Pharmaceuticals Industry Revenue by Province in China: Percentage Market Share for 2005 for Guangdong Province, Shanghai City, and Others 164 Trends 165 Demographics Encourage Growth 165

Table 107: Demographic Trends in China (2005-2010) 165 Stringent Guidelines and Standards to Boost Quality 165 OTC Drugs Leads the Profit Tables 165 Traditional Chinese Medicine to Prosper 166 Boom Time for Chinese API Suppliers 166 Consolidation to Strengthen the Industry 166 Overview 166 Outlook 166

12b. India 167 Market Overview 167 Too Fragmented Industry 167 Hot Destination for Foreign Players 167 Indian Pharmaceutical Industry to Surge 167 Contract Research to Develop Indian Pharma Industry 167 India Vies for Big Share in Pharmaceutical Outsourcing 167 Noteworthy Foreign Investments in India's Pharma Market in the Past 168 Indian Acquisitions of Foreign Operations in the Past 168 Select Indo-US Strategic Partnerships and Alliances 169 Indo-US Synergies in Pharmaceuticals 170

Table 108: Indo-US Macro Market Facts 170

Table 109: Generic Opportunities in the US and Indian Presence: 2005-2006 171

Table 110: Generic Opportunities in the US and Indian Presence: 2007 171

Table 111: Generic Opportunities in the US and Indian Presence: 2008 172

Table 112: Alliances between Select Indo-US Generic Players 172 Contract manufacturing by Indian Companies Expected to Rise Exponentially - Select Recent Strategic Alliances 172 Indian Pharma - A SWOT Analysis 173 Strengths 173 Weaknesses 173 Opportunities 173 Threats 173 Indian Pharma Sector (pre- and post- patent reform) 173 New Opportunities and Challenges for the US Players 174

Table 113: ANDA Filings by Indian Companies Exponential Growth & Potential 174

Table 114: India Only Second to the US in DMF Filings: 2003-2004 174 Growing Presence of Indian Players in Europe 175 Promoting Factors 175 Therapeutic Areas 176 Growth Strategies 176

Table 115: Contracted Pharmaceutical and Biotechnology Clinical Research, Chemical Synthesis, and Analysis Services Market for India 176 Surfacing Trends - Generic Drugs 176

Table 116: Indian Market for Generic Drugs: Annual Sales Estimates in US$ Million for bears 2003 through 2008 177 Pharma Outsourcing 177 TRIPS and Pharmaceuticals 177 Leading Pharmaceutical Companies 177

Table 117: Indian Chemical Industry Output for Pharmaceuticals: Annual Market Estimates for 2003 through 2008 in Billions of US$ 177

Table 118: Pharmaceutical Sales in India: Annual Market Estimates for 2003 through 2008 in Billions of Indian Rupees 178

Table 119: Largest Indian Companies By Market Capitalization (As Of October 2005) 178

Table 120: R&D Spend by Major Indian Pharmaceutical Companies- A Comparison from 2004 through 2008 (In US$ Million) 179

Table 121: Leading Indian Companies - FDA Approved Facilities 179

Table 122: DMF Filings By Leading Indian Companies: 2004 180

12c. Korea 180 Market Overview 180

13. Malaysia 181 Industry Overview 181 Enhancement of Pharmaceuticals 181

14. Latin America 181

14a. Brazil 181 Governing Facts 181 Initiatives 181 Market Scenario 182

Table 123: Pharmaceuticals Value Shipments in Brazil: Annual Market Estimates for 2003 through 2008 in Billions of US$ 182 Generic Drugs 182

Table 124: Brazilian Market for Generic Drugs: Annual Sales Estimates in US$ Million for Years 2003 through 2008 182

Table 125: Leading Players in Brazilian Generic Drugs Market (2004 & 2005): Percentage Breakdown of Volume Sales for Medley, EMS Sigma Pharma, Biosintetica, Eurofarma, Ranbaxy, Apotex, Merck, Novartis, and Others 183

GLOBAL DIRECTORY

To order this report: World Pharmaceuticals Market Brief

http://www.reportlinker.com/p097881/World-Pharmaceuticals-Market-Brief.html

More market research reports here!

SOURCE: ReportLinker

Reportlinker 
Nicolas: nbo@reportlinker.com 
US: (805)-652-2626 
Intl: +1 805-652-2626

Get the Answers You Need to Shape Your Strategy

- Pfizer CEO Jeff Kindler has said his company will achieve success only if it fundamentally changes the way it does business. Beyond cost cutting, what is Pfizer doing to reshape its operations? Why is Pfizer relentlessly focusing on only certain therapy areas?

- Novartis CEO Daniel Vasella has said that his company plans to mitigate some of the risk it has in its pharmaceutical business. What strategies has Novartis employed to offset the industry's traditional vulnerability to the blockbuster? What do many industry experts believe underlies much of the company's current strengths? Which of its businesses does Novartis intend to grow rapidly?

- GlaxoSmithKline's (GSK's) CEO Andrew Witty has said that his company needs to find ways to deliver more reliable growth with less risk. What actions is GSK taking to balance its business profile and change its operating model? What novel approaches is it taking to address value creation?

Scope

- Three case studies: ongoing and recent strategic initiatives at Novartis, Pfizer, and GlaxoSmithKline. How are these strategies different? How are they the same? Are any of them transformational?

- Three Spectrum, Pharma Business Strategies Scorecards: insights from company executives at GlaxoSmithKline, Novartis, and Pfizer from their presentations to investors and analysts.

- Business models and strategies: outsourcing, R&D restructuring, fully integrated pharmaceutical company (FIPCO), cost-cutting, megamergers, consolidation, decentralized management, therapy area focus, diversity, divestment, value-for-money, product differentiation, blockbuster-ready, Rx-to OTC switching, targeted acquisition.

- The state of play of pharma business strategies at three Big Pharmas: positive and negative attributes.

- Implementing transformation change: retrofitting an existing organization, the blank piece of paper, starting from scratch.

- Key business building blocks: issues surrounding customer value proposition, focus, organizational flexibility, and management.

- Five deadly pharma sins: issues relating to company stockholders, innovation, growth, customers, incremental evolution, and disruptive change.

- Four pharma business sectors: distinct characteristics, cash needs, and operating dynamics of primary care; secondary care; consumer health/OTC; and generic sectors.

Some of the Companies mentioned:

- Addex Pharmaceuticals - Alcon - Amgen - Apothecon - AstraZeneca - Bayer - Biogen - Boehringer Ingelheim - Bristol-Myers Squibb - Chiron - Eisai - Eli Lilly - Encysive Pharmaceuticals - Eon Labs - Fabrus - Genentech - General Electric - GlaxoSmithKline - ImClone Systems - Johnson & Johnson - Lagap Pharmaceuticals - Lek Pharmaceuticals - Novartis - Pfizer Global Research and Development - Praecis Pharmaceuticals - Ranbaxy Laboratories - RGo Bioscience - Rinat Neuroscience - Roche - Sabex - Sandoz - Sanofi-Aventis - Schering-Plough - Serenex - Sygenta - Takeda - Valleylabs - Warner-Lambert - Wintherix - Wyeth

For more information visit http://www.researchandmarkets.com/research/1a2cdd/pharmas_changing

SOURCE: Research and Markets

Research and Markets 
Laura Wood 
Senior Manager 
press@researchandmarkets.com 
Fax from USA: 646-607-1907 
Fax from rest of the world: +353-1-481-1716

The new report entitled Brands & Strategies Asthma also finds that patients, on the other hand, respond most favorably to the marketing messages for Advair and Xolair which focus on symptom improvement and asthma control.

Advair's message of "Fewer Asthma Symptoms, Better Breathing," appeals to a higher percentage of pulmonologists than of primary care physicians (PCPs). Surprisingly, PCPs find Xolair's message of "Allergic asthma: Do you have as much control as you should?" more appealing than pulmonologists, even though pulmonologists prescribe this drug more than PCPs do.

"PCPs treat numerous patients that have both asthma and allergic conditions such as allergic rhinitis and chronic sinusitis," said Regina Jammen, M.S., analyst at Decision Resources. "Xolair's message of control regarding allergic asthma resonates with these physicians likely as a result of the frequency with which the physicians encounter this clinical scenario."

About Brands & Strategies

The Brands & Strategies report series from Decision Resources reveals what it takes to be successful in a pharmaceutical market. It offers the most comprehensive commercial analysis of the brands and strategies of competing companies so they can better position themselves in a market and plan future strategy based on what competitors are doing. Brands & Strategies is the first and only report series to bring together all the competitive information elements pharma companies need to make informed decisions about their brands and next-steps.

About Decision Resources

Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Heather Hilty                           Elizabeth Marshall
    Decision Resources                      Decision Resources, Inc.
    781-296-2536                            781-296-2563
    hhilty@dresources.com                   emarshall@dresources.com

SOURCE Decision Resources

http://www.DecisionResources.com

Recent Highlights

-- Oncaspar-IV(TM) received orphan drug status in the EU.

-- At the October 2008 EORTC-NCI-AACR annual meeting in Geneva, Switzerland, the Company presented for the first time clinical data from its HIF-1 alpha program and new clinical data from its PEG-SN38 program; in addition the Company revealed its third Locked Nucleic Acid (LNA)-based RNA antagonist, ErbB3 (HER3).

-- The Company presented data from its LNA programs at the 4th Annual Meeting of Oligonucleotide Therapeutics Society (OTS) in Boston, Massachusetts. This meeting was the first presentation in which the Company presented the LNA-based Survivin antagonist.

Revenues

The following table reflects the revenues generated by product and segment for the three month periods ended September 30, 2008 and 2007.

                          Three Months Ended
                          (in thousands)
                          September 30, 2008        September 30, 2007        % Change
Products
Oncaspar                  $          12,492         $          10,520         19
DepoCyt                              2,201                     2,163          2
Abelcet                              6,636                     6,743          (2        )
Adagen                               7,583                     5,448          39
Total Products                       28,912                    24,874         16
Royalties                            14,611                    18,206         (20       )
Contract Manufacturing               5,267                     3,761          40
Total Revenues            $          48,790         $          46,841         4

Products Segment

The 16 percent growth in net product sales for the three months ended September 30, 2008 compared to the same period of 2007 was attributable primarily to higher revenues from Oncaspar for the treatment of Acute Lymphoblastic Leukemia (ALL), and Adagen for the treatment of a type of Severe Combined Immunodeficiency Disease (SCID). Oncaspar continues to be used and adopted in new pediatric and adult hospital and cooperative group protocols. Sales of DepoCyt, for treatment of lymphomatous meningitis, are relatively stable. Adagen tends to fluctuate from quarter-to-quarter. Abelcet, for the treatment of invasive fungal infections, continues to exhibit relative stability in a very competitive marketplace.

Royalties Segment

PEG-INTRON royalties account for the majority of our total royalty revenues. In August 2007, we sold a 25 percent interest in our future PEG-INTRON royalties. During the three months ended September 30, 2008, PEG-INTRON royalty revenue declined 26 percent compared to the prior year third quarter, in line with the portion of the royalty sold. Royalties from Pegasys in the third quarter of 2008 showed a significant increase over the corresponding quarter of 2007 due to timing of shipments to Roche. For the third quarter of 2008, we reported our first royalty from Cimzia(R). In April 2008, Cimzia was approved in the United States for the treatment of Crohn's disease. Cimzia is the first and only PEGylated anti-TNFa (Tumor Necrosis Factor alpha) antibody derived product.

Contract Manufacturing Segment

Contract manufacturing revenue for the three months ended September 30, 2008 was $5.3 million compared to $3.8 million for the comparable period of 2007. Growth from additional business and timing of shipments to our customers contributed to a 40 percent growth in revenues. The Company has been recently notified that one of its contracts will expire in 2010 and will not be renewed. The Company continues to evaluate new contract manufacturing opportunities.

Cost of Product Sales and Contract Manufacturing

The Company's cost of goods sold was $14.5 million for the three months ended September 30, 2008, compared to $14.1 million for the three months ended September 30, 2007. The gross margin this quarter increased to 58 percent. The increase is primarily due to efficiencies we have experienced as a result of the consolidation of the manufacturing facilities.

Research and Development

For the three months ended September 30, 2008, research and development expenses increased by $5.2 million to $15.7 million as compared to the three months ended September 30, 2007. We continue to invest in our research and development efforts in areas such as rhMBL, PEG-SN38, the HIF-1 alpha antagonist and other LNA- and PEGylation- based programs, as well as our next-generation lifecycle programs for Oncaspar and Adagen. The 50 percent increase this quarter is primarily due to $1.0 million in milestones related to our LNA platform program and the increase in costs associated with the efforts to improve the manufacturing processes and pharmaceutical properties of Oncaspar and Adagen. As highlighted above, we presented our first clinical data on the HIF-1 alpha antagonist program at the EORTC meeting in October. We also presented additional PEG-SN38 data and preclinical data from our Survivin program. We have recently announced our third LNA target, HER3, and data was presented at the Oligonucleotide Therapeutics Society (OTS) meeting in October. Our data continues to show promise in our very novel and innovative pipeline.

Selling, General and Administrative

Selling and marketing expenses consist primarily of sales and marketing programs to support our sales force as well as medical education. Selling and marketing expenses for the three months ended September 30, 2008 were down 2 percent from the third quarter of 2007. The decrease reflects the continued selective spending in the selling and marketing programs. General and administrative expenses increased $3.8 million primarily due to expenses related to the Company's proposed strategic initiatives.

Restructuring Charge

The Company's consolidation of all operations at the Company's South Plainfield, New Jersey facility to the Indianapolis facility are essentially complete and will be fully transferred in 2008. In connection with the restructuring program for the three months ended September 30, 2008 the Company incurred a total cost of $0.2 million compared to $5.5 million for the three months ended September 30, 2007. These costs included employee severance and related benefits for affected employees. In the third quarter of 2007, we recognized $5.1 million of remaining depreciation on South Plainfield assets which were decommissioned during the quarter.

Other Income (Expense)

Other expense for the three months ended September 30, 2008 was $1.8 million, as compared to net expense of $1.1 million for the three months ended September 30, 2007. Other (income) expense includes: net investment income, interest expense and other income or expense. Interest expense was $3.0 million for the three-month period ended September 30, 2008 compared to $4.3 million for the three-month period ended September 30, 2007. Investment income was also reduced in the third quarter of 2008 to $1.3 million. The reduction in interest expense and investment income resulted from the elimination of the remaining 4.5 percent notes.

Cash and Investments

Total cash reserves, which include cash, short-term investments, restricted investments and cash and marketable securities, were $202.5 million as of September 30, 2008, as compared to $258.2 million as of December 31, 2007. The decrease is primarily due to the repurchase and repayment of $72.4 million of our 4.5 percent notes in 2008. This decrease is partially offset by cash provided by operating activities.

Adjusted Financial Results

For the three months ended September 30, 2008, Enzon reported an adjusted net income of $0.7 million or $0.01 per diluted share, as compared to an adjusted net loss of $1.3 million or $0.03 per diluted share for the three months ended September 30, 2007.

The following table reconciles the Company's net (loss) income and net (loss) income per diluted share as determined in accordance with U.S. generally accepted accounting principles (GAAP) to its adjusted net income (loss) and net income (loss) per diluted share for the three months ended September 30, 2008 and 2007 respectively:

                                                                       Three Months Ended
                                                                       (in thousands, except per-share amounts)
                                                                       September 30, 2008                                                        September 30, 2007
                                                                       Net                      Net (loss) income per diluted share (4)          Net                     Net income
                                                                       (Loss) Income                                                             Income (loss)           (loss) per diluted share (5)
GAAP net (loss) income                                                 $ (2,020  )              $(0.05               )                           $87,530                 $1.23
Adjustment to GAAP net loss:
Add: Costs related with the proposed strategic initiatives (1)         2,694                    -
Less: Gain related to the repurchase of debt (2)                                                                                                 (182     )              -
Less: Gain on sale of royalty asset (3)                                                                                                          (88,666  )              -
Adjusted net income (loss) (6)                                         $ 674                    $0.01                                            $(1,318  )              $(0.03          )
(1) Adjusted financial results for the
third quarter of 2008 exclude the costs related with the Company's
proposed strategic initiatives (spin-off of the Company's
biotechnology business or sale of the specialty pharmaceutical
business).
(2) The Company's adjusted financial
results for the third quarter of 2007 exclude a gain
related
to the repurchase and repayment of the 4.5% Notes.
(3) The Company's adjusted financial
results for the third quarter of 2007 exclude a gain on the sale
of a 25% interest in future royalties on sales of PEG-INTRON by
Schering-Plough Corporation of $88.7 million.
(4) Computation of adjusted diluted
earnings per share includes certain contingently issuable shares
whereas GAAP loss per share does not. Per-share computation of
individual reconciling items is not meaningful.
(5) Computation of diluted GAAP earnings
per share includes certain contingently issuable shares and the
assumed conversion of notes payable and the add-back of interest
expense; no such adjustments are included in the computation of
adjusted diluted loss per share. Per- share computation of
individual reconciling items is not meaningful.
(6) Adjusted net income (loss) and
adjusted net income (loss) per share, as Enzon defines them, may
differ from similarly named measures used by other entities, and
consequently, could be misleading unless all entities calculated
and defined such items in the same manner. The Company believes
that investors' understanding of its performance is enhanced by
disclosing adjusted net income (loss) and adjusted net income
(loss) per share reflecting adjustments for certain items that the
Company deems to be non-recurring.

Conference Call and Webcast

Enzon will be hosting a live conference call today, November 5, 2008 at 9:00 am Eastern Time (ET). All interested parties may access the call by using the following information:

Domestic Dial-In Number:         (866) 334-4934
International Dial-In Number:    (416) 849-4293
Access Code:                     Enzon

Enzon's conference call will also be available via live audio webcast at www.investorcalendar.com. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will be available following the call. The rebroadcast will begin on Wednesday, November 5, 2008, at approximately 12:00 p.m. Eastern Time (ET) and end on November 12, 2008, at approximately 12:00 p.m. Eastern Time (ET). The rebroadcast may be accessed using the following information:

Domestic Dial-In Number:         (866) 245-6755
International Dial-In Number:    (416) 915-1035
Access Code:                     98757

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon's products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the period ended December 31, 2007. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.

Enzon Pharmaceuticals, Inc. and Subsidiaries
Consolidated Statements of Operations
Three Months ended September 30, 2008 and 2007
(In thousands, except per share amounts)
(Unaudited)
                                                          September30,              September30,
                                                          2008                      2007
Revenues:
Product sales, net                                        $ 28,912                  $24,874
Royalties                                                 14,611                    18,206
Contract manufacturing                                    5,267                     3,761
Total revenues                                            48,790                    46,841
Costs and expenses:
Cost of product sales and contract manufacturing          14,473                    14,118
Research and development                                  15,654                    10,456
Selling, general and administrative                       18,253                    14,632
Amortization of acquired intangible assets                167                       171
Restructuring charge                                      249                       5,513
Total costs and expenses                                  48,796                    44,890
Gain on sale of royalty interest, net                     -                         88,666
Operating (loss) income                                   (6        )               90,617
Other income (expense):
Investment income, net                                    1,268                     2,689
Interest expense                                          (3,025    )               (4,286   )
Other, net                                                (94       )               497
                                                          (1,851    )               (1,100   )
(Loss) income before income tax provision                 (1,857    )               89,517
Income tax provision                                      163                       1,987
Net (loss) income                                         $(2,020   )               $87,530
(Loss) earnings per common share -- basic                 $ (0.05   )               $ 1.99
(Loss) earnings per common share -- diluted               $ (0.05   )               $ 1.23
Weighted average shares -- basic                          44,464                    43,925
Weighted average shares -- diluted                        44,464                    74,344

Enzon Pharmaceuticals, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
September 30, 2008 and December 31, 2007
(In thousands)
(Unaudited)
                                                        September30,            December31,
                                                        2008                    2007
Assets
Current assets:
Cash and short-term investments                         $136,031                $163,960
Restricted investments and cash                         -                       73,592
Accounts receivable, net                                15,262                  14,927
Inventories                                             16,804                  22,297
Other current assets                                    6,155                   6,401
Total current assets                                    174,252                 281,177
Property and equipment, net                             45,006                  45,312
Other assets:
Marketable securities                                   66,479                  20,653
Amortizable intangible assets, net                      63,366                  68,141
Other assets                                            4,247                   5,074
                                                        134,092                 93,868
Total assets                                            $353,350                $420,357
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses                   $36,228                 $33,091
Notes payable                                           -                       72,391
Total current liabilities                               36,228                  105,482
Notes payable                                           275,000                 275,000
Other liabilities                                       3,924                   3,302
Total liabilities                                       315,152                 383,784
Stockholders' equity                                    38,198                  36,573
Total liabilities and stockholders' equity              $353,350                $420,357
Common shares outstanding                               44,896                  44,200

SOURCE: Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc. 
Craig Tooman, 908-541-8777 
EVP, Finance and Chief Financial Officer